News >

Pembrolizumab Continues to Demonstrate Long-Term Efficacy in Melanoma

Brielle Urciuoli
Published: Sunday, Feb 18, 2018

Eric Whitman, MD

Eric Whitman, MD
The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma, according to a presentation by Eric Whitman, MD, at the 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies.

Whitman, medical director of Atlantic Health System Cancer Care and director of the Atlantic Melanoma Center, cited the final results from the phase III KEYNOTE-006 study, which randomized 834 patients with unresectable stage III or stage IV advanced melanoma to 4 cycles of ipilimumab (Yervoy) at 3 mg/kg every 3 weeks (n = 278); 10 mg/kg of pembrolizumab every 3 weeks (n = 277); or 10 mg/kg of pembrolizumab every 2 weeks (n = 279).1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication